Cargando…
Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi
PURPOSE: To describe the cost of treating diffuse large B-cell lymphoma (DLBCL) in Malawi under the following circumstances: (1) palliation only, (2) first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), (3) salvage etoposide, ifosfamide, and cisplatin (EPIC), and (4) salvage...
Autores principales: | Painschab, Matthew S., Kohler, Racquel E., Kasonkanji, Edwards, Zuze, Takondwa, Kaimila, Bongani, Nyasosela, Richard, Nyirenda, Ruth, Krysiak, Robert, Gopal, Satish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690619/ https://www.ncbi.nlm.nih.gov/pubmed/31322992 http://dx.doi.org/10.1200/JGO.19.00059 |
Ejemplares similares
-
Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis
por: Painschab, Matthew S, et al.
Publicado: (2021) -
Plasmablastic lymphoma in Malawi
por: Zuze, Takondwa, et al.
Publicado: (2018) -
Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial
por: Kimani, Stephen, et al.
Publicado: (2021) -
High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi
por: Montgomery, Nathan D., et al.
Publicado: (2019) -
Rosai‐Dorfman disease in Malawi
por: Kasonkanji, Edwards, et al.
Publicado: (2018)